Background: The treatment success rate of drug-resistant (DR) tuberculosis is alarmingly low. Therefore, more effective and less complex regimens are urgently required. Methods: We compared the efficacy of an all oral DR tuberculosis drug regimen consisting of bedaquiline (25 mg/kg), delamanid (2.5 mg/kg), and linezolid (100 mg/kg) (BDL) on the mycobacterial load in the lungs and spleen of tuberculosis-infected mice during a treatment period of 24 weeks. This treatment was compared with the standard regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE). Relapse was assessed 12 weeks after treatment. Two logistic regression models were developed to compare the efficacy of both regimens. Results: Culture negativity in the lung...
Tuberculosis (TB) is the ninth cause of global death, more than any other infectious disease. With g...
The favorable treatment outcome rate for multidrug-resistant tuberculosis (MDR-TB) is only 54%, and ...
The new drugs delamanid and bedaquiline are increasingly being used to treat multidrug-resistant (MD...
OBJECTIVES: Non-replicating persistent Mycobacterium tuberculosis is difficult to kill since the org...
Linezolid is clinically effective against multidrug-resistant tuberculosis and is part of the shorte...
Extensively drug-resistant tuberculosis (XDR-TB) on top of being a growing public health concern, re...
Background Given the persistently high global burden of tuberculosis, effective and shorter treatmen...
textabstractPreclinical treatment outcome evaluation of tuberculosis (TB) occurs primarily in mice. ...
ABSTRACT Multidrug-resistant and extensively drug-resistant tuberculosis (MDR-TB and XDR-TB, respect...
John D Szumowski,1,2 John B Lynch11Division of Allergy and Infectious Diseases, Department of Medici...
Novel oral regimens composed of new drugs with potent activity againstMycobacterium tuberculosis and...
Tuberculosis (TB) continues to cause more deaths worldwide than any other single infectious disease....
Introduction: In recent years, a pressing need to develop new, effective and safe drugs against tube...
BACKGROUND: The bedaquiline-pretomanid-linezolid regimen has been reported to have 90% efficacy agai...
The new drugs delamanid and bedaquiline are increasingly being used to treat multidrug-resistant (MD...
Tuberculosis (TB) is the ninth cause of global death, more than any other infectious disease. With g...
The favorable treatment outcome rate for multidrug-resistant tuberculosis (MDR-TB) is only 54%, and ...
The new drugs delamanid and bedaquiline are increasingly being used to treat multidrug-resistant (MD...
OBJECTIVES: Non-replicating persistent Mycobacterium tuberculosis is difficult to kill since the org...
Linezolid is clinically effective against multidrug-resistant tuberculosis and is part of the shorte...
Extensively drug-resistant tuberculosis (XDR-TB) on top of being a growing public health concern, re...
Background Given the persistently high global burden of tuberculosis, effective and shorter treatmen...
textabstractPreclinical treatment outcome evaluation of tuberculosis (TB) occurs primarily in mice. ...
ABSTRACT Multidrug-resistant and extensively drug-resistant tuberculosis (MDR-TB and XDR-TB, respect...
John D Szumowski,1,2 John B Lynch11Division of Allergy and Infectious Diseases, Department of Medici...
Novel oral regimens composed of new drugs with potent activity againstMycobacterium tuberculosis and...
Tuberculosis (TB) continues to cause more deaths worldwide than any other single infectious disease....
Introduction: In recent years, a pressing need to develop new, effective and safe drugs against tube...
BACKGROUND: The bedaquiline-pretomanid-linezolid regimen has been reported to have 90% efficacy agai...
The new drugs delamanid and bedaquiline are increasingly being used to treat multidrug-resistant (MD...
Tuberculosis (TB) is the ninth cause of global death, more than any other infectious disease. With g...
The favorable treatment outcome rate for multidrug-resistant tuberculosis (MDR-TB) is only 54%, and ...
The new drugs delamanid and bedaquiline are increasingly being used to treat multidrug-resistant (MD...